Evidence map›Paper›PMID 36379708›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2023

A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various

Shen Cheng, Darcy R Flora, Allan E Rettie, Richard C Brundage, Timothy S Tracy

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shen ChengDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Twin Cities, Minnesota (S.C., D.R.F., R.C.B.); Tracy Consultants, Huntsville, Alabama (T.S.T.); and Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington (A.E.R.).
Darcy R FloraDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Twin Cities, Minnesota (S.C., D.R.F., R.C.B.); Tracy Consultants, Huntsville, Alabama (T.S.T.); and Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington (A.E.R.).
Allan E RettieDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Twin Cities, Minnesota (S.C., D.R.F., R.C.B.); Tracy Consultants, Huntsville, Alabama (T.S.T.); and Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington (A.E.R.).
Richard C BrundageDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Twin Cities, Minnesota (S.C., D.R.F., R.C.B.); Tracy Consultants, Huntsville, Alabama (T.S.T.); and Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington (A.E.R.) brund001@umn.edu.ORCID 0000-0003-4465-5036
Timothy S TracyDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Twin Cities, Minnesota (S.C., D.R.F., R.C.B.); Tracy Consultants, Huntsville, Alabama (T.S.T.); and Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington (A.E.R.).
University of Minnesota · US

Funding

TOXIC DRUG INTERACTIONS WITH VALPROIC ACIDP01GM032165 · NIGMS · UNIVERSITY OF WASHINGTON · PI RETTIE, ALLAN EDWARD · 1985 to 2012
$18.3M
Pharmacogenetics and Drug InteractionsR01GM069753 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BRUNDAGE, RICHARD C · 2004 to 2012
$2.5M
NIGMS NIH HHS P01 GM032165NIGMS NIH HHS R01 GM069753
6 · The paper itself

Abstract

Warfarin, a commonly prescribed oral anticoagulant medication, is highly effective in treating deep vein thrombosis and pulmonary embolism. However, the clinical dosing of warfarin is complicated by high interindividual variability in drug exposure and response and its narrow therapeutic index.

Indexed as

AnticoagulantsWarfarinCytochrome P-450 CYP2C9GenotypeHumansModels, BiologicalPolymorphism, GeneticAnticoagulantsCYP2C9 protein, humanCytochrome P-450 CYP2C9Warfarin

Identifiers

PMID36379708
PMCPMC9901215
OpenAlexW4309162477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.